A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
← catalyst calendarNCT07766005 · readout ≤ 438 d
Sponsored by Spyre Therapeutics, Inc. (industry) · SYRE — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
150estimated
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Oct 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa (HS)
Interventions
- Drug: SPY072 — also filed as SPY002-072
- Drug: Placebo
- Drug: bimekizumab
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)
measured Week 16
Permalink · SYRE's whole pipeline · Catalyst calendar · Every registered study · What changed